Raloxifene
Indication
Primary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA160)
NICE TA160 - Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
Black
Brand:
Nice TA:
160
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
LSCMMG is adopting the local decision made prior to April 2013
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: